Literature DB >> 10190728

Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels.

L Albornoz1, D Alvarez, J C Otaso, A Gadano, J Salviú, S Gerona, P Sorroche, A Villamil, R Mastai.   

Abstract

BACKGROUND/AIMS: The aim of this study was to evaluate the relationship between plasma levels of von Willebrand factor (vWF), a marker of endothelial cell activation, and nitric oxide, a powerful vasodilator synthesized by endothelial cells, in 27 patients with cirrhosis at different stages of the disease. These results were compared with those of age-matched normal, healthy subjects (n=10).
METHODS: vWF:antigen was measured by electro-immunodiffusion test and serum nitrite and nitrate levels, the stable end products of nitric oxide metabolism, were determined by an enzymatic procedure.
RESULTS: vWF:antigen and nitrite/nitrate levels were significantly higher in cirrhotic patients (367+/-185% and 29.3+/-10.8 micromol/l) than in healthy subjects (92+/-20% and 19.2+/-8.3 micromol/l, p<0.05, respectively). Higher levels of vWF:antigen and nitrites/nitrates were observed in patients with more advanced degrees of liver failure, as reflected by quantitative Child-Pugh's score (516+/-154% and 38.3+/-7.8 micromol/l in Child-Pugh > or = 9 vs 227+/-61% and 21.0+/-6.1 micromol/l in Child-Pugh <9, p<0.001, respectively). Moreover, both endothelial-related factors were higher in patients with ascites than those without ascites (543+/-158% and 37.8+/-8.9 micromol/l vs 262+/-103% and 24.4+/-8.8 micromol/l, p<0.001, respectively). In the overall series, a highly significant linear correlation between nitrites/nitrates and vWF:antigen levels was observed in patients with cirrhosis (r=0.79, p<0.001).
CONCLUSIONS: These results support a cirrhosis-related endothelial dysfunction and suggest that plasma vWF measurement could be useful as a marker of endothelial disturbance in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190728     DOI: 10.1016/s0168-8278(99)80104-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

Review 1.  New insights into the coagulopathy of liver disease and liver transplantation.

Authors:  M Senzolo; P Burra; E Cholongitas; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.

Authors:  Georgios N Kalambokis; Gerasimos Baltayiannis; Dimitrios Christodoulou
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

3.  Significant Association between Serum Levels of Von Willebrand Factor (vWF) Antigen with Stages of Cirrhosis.

Authors:  Vural Taner Yilmaz; Dinc Dincer; Ali Berkant Avci; Ramazan Cetinkaya
Journal:  Eurasian J Med       Date:  2015-02

4.  Clinical significance of plasma D-dimer and von Willebrand factor levels in patients with ulcer colitis.

Authors:  Gang Xu; Ke-Li Tian; Guo-Ping Liu; Xue-Jun Zhong; Shao-Ling Tang; Yan-Ping Sun
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 5.  Relevance of ADAMTS13 to liver transplantation and surgery.

Authors:  Saiho Ko; Hisanao Chisuwa; Masanori Matsumoto; Yoshihiro Fujimura; Eiji Okano; Yoshiyuki Nakajima
Journal:  World J Hepatol       Date:  2015-07-08

Review 6.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

7.  Endothelial markers in schistosomiasis patients with or without portal hypertension.

Authors:  Carlos Fischer de Toledo; Claudia Teresa Carvente; David Carlos Shigueoka; Durval Rosa Borges
Journal:  Dig Dis Sci       Date:  2008-08-27       Impact factor: 3.199

8.  A comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis.

Authors:  Bing He; Hao Zhang; Tieliu Shi
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

9.  Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hepatol       Date:  2011-07-18

10.  Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients.

Authors:  Rosa Ayala; Joaquín Martínez-López; Teresa Cedena; Rosalía Bustelos; Carlos Jimenez; Enrique Moreno; Carmen Ribera
Journal:  BMC Gastroenterol       Date:  2011-11-28       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.